Ad
PSTV Stock Quote Trading Chart PLUS THERAPEUTICS Inc.
home / stock / pstv / pstv quote
Quote | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
| Last: | $ |
|---|---|
| Change Percent: | 2.29% |
| Open: | $2.15 |
| Close: | $2.23 |
| High: | $2.29 |
| Low: | $2.15 |
| Volume: | 51,911 |
| Last Trade Date Time: | 02/12/2020 04:43:17 pm |
Quotes are delayed by 15 to 20 minutes.
PSTV Last Five Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $ | $2.15 | $2.23 | $2.29 | $2.15 | 51,911 | 02-12-2020 |
| $ | $2.15 | $2.18 | $2.20 | $2.10 | 25,939 | 02-11-2020 |
| $ | $2.17 | $2.165 | $2.1994 | $2.12 | 21,896 | 02-10-2020 |
| $ | $2.24 | $2.17 | $2.24 | $2.16 | 29,417 | 02-07-2020 |
| $ | $2.22 | $2.21 | $2.24 | $2.1356 | 40,541 | 02-06-2020 |
| $ | $2.29 | $2.23 | $2.30 | $2.15 | 39,597 | 02-05-2020 |
| $ | $2.21 | $2.26 | $2.30 | $2.10 | 60,207 | 02-04-2020 |
| $ | $2.16 | $2.20 | $2.26 | $2.15 | 34,621 | 02-03-2020 |
| $ | $2.15 | $2.18 | $2.24 | $2.1387 | 51,183 | 01-31-2020 |
| $ | $2.25 | $2.21 | $2.29 | $2.10 | 79,714 | 01-30-2020 |
| $ | $2.34 | $2.27 | $2.3497 | $2.23 | 55,807 | 01-29-2020 |
| $ | $2.32 | $2.32 | $2.39 | $2.31 | 24,819 | 01-28-2020 |
| $ | $2.30 | $2.33 | $2.40 | $2.19 | 41,151 | 01-27-2020 |
| $ | $2.49 | $2.33 | $2.50 | $2.26 | 159,828 | 01-24-2020 |
| $ | $2.50 | $2.495 | $2.5599 | $2.42 | 29,533 | 01-23-2020 |
| $ | $2.59 | $2.50 | $2.6569 | $2.50 | 86,220 | 01-22-2020 |
| $ | $2.66 | $2.5665 | $2.80 | $2.51 | 115,931 | 01-21-2020 |
| $ | $2.75 | $2.71 | $2.86 | $2.68 | 83,828 | 01-20-2020 |
| $ | $2.75 | $2.71 | $2.86 | $2.68 | 83,694 | 01-17-2020 |
| $ | $2.70 | $2.72 | $2.94 | $2.6915 | 117,831 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
Ad
-
AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compa...
-
AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced th...
-
Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive Median progression free survival (mPFS) is 11 mon...